Navigation Links
Mount Sinai leads Consortium of Food Allergy Research with $29.9 million grant
Date:8/12/2010

Mount Sinai School of Medicine today announced that the National Institutes of Health (NIH) has renewed its funding of the Consortium of Food Allergy Research (CoFAR), providing an additional $29.9 million toward genetic research and the prevention and treatment of food allergy. Mount Sinai is the primary research site for CoFAR, leading seven other institutions around the country.

Under the renewed grant, Mount Sinai researchers will continue several clinical trials evaluating immunotherapies for peanut and egg allergy. In two of the studies, researchers are determining whether an extract of peanut protein under the tongue or ingesting increasing amounts of egg protein improves tolerance. In another trial, researchers administer gradually increased doses of peanut protein to patients in a suppository to treat the allergy. The Mount Sinai team will also initiate a new trial studying the use of a peanut protein patch applied to the skin to treat peanut allergy. CoFAR is also conducting an observational study that has enrolled more than 500 infants to determine what factors worsen or improve their allergies.

"We are excited about the progress we have made in understanding food allergy in children over the last five years," said Hugh Sampson, MD, Professor, Pediatrics, Chief, Division of Allergy & Immunology, Director of the Jaffe Food Allergy Institute, Mount Sinai School of Medicine and lead investigator on CoFAR. "With the renewal of this grant, we will expand our research and hopefully move closer toward ending the widespread impact of food allergy."

The grant will also fund new genetic research on eosinophilic gastrointestinal diseases (EGIDs), a new group of allergic diseases. According to the NIH, the most common EGID is eosinophilic esophagitis. The main symptoms in children include nausea, vomiting, and abdominal pain after eating. Three new CoFAR trial sites at Cincinnati Children's Medical Center Hospital, University of Colorado at Denver, and Children's Hospital of Philadelphia will conduct the research.

Dr. Sampson will remain principal investigator of the five original CoFAR sites: The Mount Sinai Medical Center, Duke University Medical Center, Johns Hopkins University, National Jewish Health in Denver, and University of Arkansas for Medical Sciences. CoFAR is currently enrolling patients for the trials evaluating treatment with peanut protein administered orally and through the skin patch.

Funding for CoFAR is provided by the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases, components of NIH.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen
2. Chicago Father and Son Team to Climb Mount Kilimanjaro for ShelterBox
3. AAU Big Mountain Jam Basketball Tournament To Be Played On SnapSports Flooring
4. Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
5. Women who consume large amounts of tea have increased risk of rheumatoid arthritis
6. Albeo Releases Six New Surface Mount LED Lighting Fixtures
7. Green Drinks NYC and Green Mountain Energy Company Present Summer Bash at Solar One
8. The Mount Sinai Hospital Ranked in Top 25 of Best Children's Hospitals in Two Specialties by U.S. News & World Report
9. Mount Sinai researchers approaching universal treatment for all strains of influenza
10. Mountain Retreat for Women Whose Lives Have Been Touched by Cancer
11. Mount Sinai researchers move closer to a universal influenza vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... management assistance and personal financial planning services to residents of southern New Hampshire, ... charity event that promises to fight hunger and homelessness in the region. , ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National Basketball ... NBSCA Strength & Conditioning Coach of the Year. , In its 11th year, ... the coach who embodies the highest level of excellence and outstanding service to their ...
(Date:6/26/2017)... ... ... Torrance dentist, Dr. Robert Mondavi DDS , is now offering comprehensive cosmetic ... person’s appearance. A healthy, radiant smile can make a person look more attractive, youthful, ... the smile of their dreams with cosmetic dentistry. , “The field of dentistry is ...
(Date:6/26/2017)... Ruidoso, New Mexico (PRWEB) , ... June 26, ... ... sexual dysfunction, anorgasmia, and urinary leakage is revolutionizing the way women look and ... Mexico is tackling the problem of female sexual dysfunction and urinary leakage head ...
(Date:6/25/2017)... ... 25, 2017 , ... FCPX LUT Vintage Volume 2 for Final Cut Pro ... Vintage Volume 2 contains 60 different color-grade presets, giving editors multiple options for adding ... to single out subjects, plus much more. FCPX LUT Vintage Volume 2 is designed ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy & Homecare is ... the United States . The Raizer is a ... fallen person up to an almost-standing position within ... operated by one assistant and does not require ... enough that a child can operate it, and ...
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: